With the Falsified Medicine Directive (FMD) now in effect, Alloga is fully compliant with the regulatory requirements
Counterfeit medicines can be enormously problematic for the pharmaceutical industry, leading to the loss of patient confidence as well as to a loss of revenue. The European Falsified Medicines Directive (FMD) went live on 9 February 2019, with the aim of reducing the number of falsified medicines entering the European medicines supply chain.
Verification & Decommissioning
According to the EU FMD, products must be verified and decommissioned by a hospital or pharmacy before being dispensed to the patient. Alloga can verify and decommission products on behalf of manufacturers for Article 23 customers. Institutions covered by Article 23 depending on the EU country include veterinarians, paramedics and emergency medical practitioners, hospices, prisons and nursing homes, amongst others.
Alloga’s market leading technology supports robust and flexible integrations with internal logistics management systems. Learn more about our platforms and integration services here.